

---

# S&P TEST

SWOT & PESTLE.com

---

## BIOCON LIMITED SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Biocon Limited

**Company Sector :** Biopharmaceuticals

**Operating Geography :** India, Asia, Global

**About the Company :**

Biocon Limited is an Indian biopharmaceutical company that was founded in 1978 by Kiran Mazumdar-Shaw. The headquarters of the company are in Bangalore, Karnataka, India. Biocon manufactures and sells generic active pharmaceutical ingredients (APIs) in nearly 120 countries, including the United States and Europe. In addition, the biotechnology firm develops innovative biologics, biosimilar insulins, and antibodies. Biocon's biosimilar products are available in various emerging markets in both bulk and formulation forms. Metabolics, oncology, immunotherapy, and nephrology products are among Biocon's formulations for the Indian market. INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab), and KRABEVA (Bevacizumab) are all Biocon brands. Syngene International Limited (Syngene) is a publicly traded subsidiary of Biocon that works in the contract research and development industry. Biocon and Syngene employ a total of 16,545 people. In November 2023, Biocon Biologics relinquished two non-core branded medicines in India. In October 2023, Biocon was placed No. 8 on Science Magazine's list of the Best Employers in the Global Biotech and Pharma Sector.

Biocon Limited's USP lies in improving global healthcare by developing innovative and cost-effective biopharmaceuticals for patients, partners, and healthcare systems worldwide. Its objective is to be a world-class integrated biotechnology enterprise.

**Revenue :**

INR 11,550 crore- FY ending 31st March 2023 (y-o-y growth 38%)

INR 8,397 crore- FY ending 31st March 2022

## SWOT Analysis :

The SWOT Analysis for Biocon Limited is given below:

Strengths	Weaknesses
<ol style="list-style-type: none"> <li>1.Viatris acquisition bolsters Biocon Biologics with expanded global treatment portfolio.</li> <li>2. Biocon operates in about 120 countries, reaching a wide and varied market.</li> <li>3.Learning biopharmaceuticals leader with multiple value propositions across its verticals</li> <li>4.Emphasizes research to provide affordable treatments for unmet patient needs.</li> </ol>	<ol style="list-style-type: none"> <li>1.Biocon's heavy reliance on key products is a vulnerability.</li> <li>2.Value chain disruptions can disrupt operations, affecting supply and raising costs.</li> </ol>
Opportunities	Threats
<ol style="list-style-type: none"> <li>1.Affordable medicine prices open avenues for broader market expansion.</li> <li>2.Leveraging digital solutions can enhance operational efficiency and effectiveness.</li> <li>3.Transformative partnership with Tabuk Pharmaceuticals to help gain foothold in Middle East region</li> <li>4.Global generic drug market expected to rise from \$414B (2021) to \$574B (2027).</li> </ol>	<ol style="list-style-type: none"> <li>1.Growing competition and pricing challenges in specific markets.</li> <li>2.Economic downturn may lower Biocon's demand and profitability</li> </ol>

## PESTLE Analysis :

The PESTLE Analysis for Biocon Limited is given below:

Political	Economical
1.India's PLI scheme may enhance Biocon's manufacturing environment.	1.Economic slowdown and conflicts can impact Biocon. 2.Growing biosimilar adoption, small molecule generics to dominate two-thirds market share.
Social	Technological
1.The growing emphasis on ESG factors impacts Biocon's evaluation and reputation. 2.Consumer shift to eco-friendly products risks reputation if expectations aren't met.	1.Introducing API Customer Portal for enhanced interactions, information access, rapid responses, and order monitoring 2.Integrating manufacturing with automation, artificial intelligence and Industry 4.0 technologies
Legal	Environmental
1.Adhering to strict regulations, including FDA guidelines, is essential for Biocon. 2.U.S. biosimilar rules are stringent, demanding more studies, potentially increasing costs. 3. UK MHRA's May'22 guidance eliminates Phase III trial, cutting development time and costs.	1.Rising environmental and ethical awareness in healthcare 2.Focusing on clean energy transition in operations

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Biocon Limited** SWOT & PESTLE Analysis is a paid report at **27.53 U.S.D.**

**Buy Now**

\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
**[support@swotandpestle.com](mailto:support@swotandpestle.com)**